Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Relora supplement launch

This article was originally published in The Tan Sheet

Executive Summary

Next Pharmaceuticals in discussions with Pharmavite, Natrol, PureTec for potential distribution of Relora-containing supplements in mass market channels, and with Nutraceutical Corp. for health food store sales. Products expected to be in all distribution channels in 30-60 days, ingredient supplier says. Relora contains proprietary plant extract from Magnolia officinalis and Phellodendron amurense and is manufactured by RJ Reynolds' Avoca division (1"The Tan Sheet" March 20, 2000, In Brief). Next is positioning the ingredient as a kava alternative, says it is "clinically shown to significantly alter the hormone levels associated with stress-induced obesity"...

You may also be interested in...



Joe Camel "supplements" his portfolio

RJ Reynolds Tobacco Company's Avoca division and Next Pharmaceuticals have partnered to develop proprietary dietary supplement ingredients, the firms announce March 8. Flagship Nextracts include the COX-2 anti-inflammatory Nexprofen and Relora, a phenolic complex for anxiety and stress. Others are Standardized Echinacea Purpurea Nextract with 4% phenolic compounds and four Standardized Saw Palmetto Nextracts containing 10%, 25%, 30% and 40% total fatty acids, respectively. The January agreement follows 18 months of R&D; the agricultural and extraction facilities are located at Avoca's 2,400-acre North Carolina facility. Next is courting large pharmaceutical and supplement companies as part of the ingredients' "roll-out" phase

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel